On June 11, 2025, the Delaware Court of Chancery found Alexion Pharmaceuticals liable for more than $180 million in damages to former stockholders of Syntimmune, Inc., following the Court’s September 2024 ruling that Alexion...more
6/19/2025
/ Biotechnology ,
Breach of Contract ,
Clinical Trials ,
Commercially Reasonable Efforts ,
Contract Disputes ,
Contract Terms ,
Damages ,
Life Sciences ,
Merger Agreements ,
Mergers ,
Pharmaceutical Industry
On July 9, 2021, the Delaware Court of Chancery (Slights, V.C.) issued an opinion in Bardy Diagnostics, Inc. v. Hill-Rom, Inc., No. 2021-0175-JRS, concluding that the requirements of a “material adverse effect” (“MAE”) clause...more
Goodwin Procter’s Business Litigation Reporter provides timely summaries of key cases and other developments within dedicated Business Litigation sessions and related courts throughout the country – courts within which...more
6/13/2016
/ Arbitration ,
Arbitration Awards ,
Arbitrators ,
Books & Records ,
Choice-of-Law ,
Closely Held Businesses ,
Common-Interest Privilege ,
Corporate Officers ,
Demand Futility ,
Derivative Suit ,
Employment Contract ,
Federal Trade Commission (FTC) ,
Joint and Several Liability ,
Judicial Review ,
Jurisdiction ,
Merger Clause ,
Mergers ,
Personal Liability ,
Preliminary Injunctions ,
Registration Statement ,
Restitution ,
Shareholders ,
Summary Judgment ,
Tortious Interference ,
Trade Dress ,
Trademark Infringement